EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
KNOWLEDGE BANK
-
Articles
Beyond Traditional Signal Detection: Advancing Pharmacovigilance Through Quantitative Epidemiology
The emergence of increasingly targeted medicines is changing the questions that pharmacovigilance must answer Antibodydrug conjugates cellular therapies genebased treatments and other advanced modalities can provide substantial therapeutic benefit yet their safety profiles may reflect complex biological mechanisms heterogeneous patient populations and delayed effects Detecting a numerical imbalanc...
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Pfizer Plans US$650 Million Manufacturing Technology Center at Groton R&D Campus in Connecticut
Pfizer plans to build a Manufacturing Technology Center at its research and development campus in Groton Connecticut representing a US million capital investment over the next five years The facility will produce clinical active pharmaceutical
-
Research Insights
Single-cell transcriptomics and machine learning characterize LTA4H-linked lipid metabolism and inflammatory signatures in the knee osteoarthritis IPFP/synovium compartment
Knee osteoarthritis KOA is a wholejoint disease characterized by inflammation immune dysregulation and metabolic imbalance
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Innovative Solutions: Exploring Cutting-Edge Fill-Finish Technologies in Pharma Manufacturing
Kate Williamson
The article explores the evolution, innovations, benefits, challenges, and future trends of cutting-edge fill-finish technologies in pharmaceutical manufacturing. It emphasizes improved product qualit...
-
2
Forgotten Biology: The Missing Link Behind Trial Outcomes
Dr. Sachin Dighe
Mr. Jayesh Chaudhary
Trial failure is not always a product failure; often, it is a population-design failure. This article explores how overlooked biological heterogeneity weakens signals, obscures efficacy and undermines...
-
3
The Latest Breakthroughs in Prescription Drug Development
Kate Williamson
New classes of prescription drugs include but are not limited to the following; Personalized medicine; mRNA; gene therapy; Artificial intelligence in drug discovery; Biologics; Long acting formulation...
-
4
Advancing Pharmaceutical Manufacturing Through Innovation and Regulatory Preparedness
Lakshmi
American pharmaceutical manufacturing is being reshaped by two forces at once: a wave of advanced production technologies and a regulator that now rewards early, transparent engagement. FDA initiative...
-
5
The Outsourcing Advantage: Why Pharma’s Next Competitive Edge Will Be Built Through Ecosystems
Deepak Khurana
As pharmaceutical innovation becomes increasingly complex, strategic outsourcing has emerged as a critical growth enabler. Beyond cost optimisation, it provides access to specialised capabilities, acc...
press releasesRead more...
Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery
As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company
Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing
Guardant Health Inc Nasdaq GH a leading precision oncology company today announced the US clinical launch of Guardant Reveal Ultra a new molecular residual disease MRD platform for solid tumors offering personalized ultrasensitive
Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
Sonic Incytes Medical Corp developer of the Velacur pointofcare liver assessment platform today announced a multiyear partnership with Madrigal Pharmaceuticals Inc Nasdaq MDGL a biopharmaceutical company focused on delivering novel
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Regeneron Pharmaceuticals Inc NASDAQ REGN today announced that the US Food and Drug Administration FDA has approved Livsayis cemdisiran for the treatment of generalized myasthenia gravis gMG in adult patients
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
03 - 04
Dec 2026Infectious and Rare Diseases
Paris, France
LATEST NEWSRead more...
Regeneron Secures FDA Approval for Livsayis, the Seventh Approved Therapy from Alnylam's RNAi Platform
Regeneron has received approval from the US Food and Drug Administration FDA for Livsayis cemdisiran an RNA interference RNAi therapeutic for adults with generalised myasthenia gravis gMG The approval marks the seventh FDAapproved medicine originating from Alnylam Pharmaceuticals RNAi platform in le...
Nanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY Across the GCC Region
Nanoscope Therapeutics has entered into an agreement with Uniphar to expand access to its investigational retinal gene therapy MOGENRY sonpiretigene isteparvovec MCO across the six member states of the Gulf Cooperation Council
Scientist.com Launches AI-Ready Market Intelligence Platform for Biopharma R&D
Scientistcom has launched Pharma Observatory a market intelligence platform designed to help biopharmaceutical research and development RD teams understand the competitive landscape surrounding their programmes The platform provides insights into competing research programmes potential business part...
Erasca Partners with Bristol Myers Squibb to Evaluate ERAS-0015 Combination Therapy for Pancreatic Cancer
Clinicalstage precision oncology company Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS to evaluate its investigational drug ERAS in combination with navlimetostat BMS an investigational PRMT inhibitor developed by BMS
GATC Health and Hesperos Join Forces to Develop AI and Human-on-a-Chip Workflow for Preclinical Testing
GATC Health Corp and Hesperos Inc have entered into a strategic collaboration to develop an integrated New Approach Methodologies NAMs workflow aimed at reducing the time and cost of preclinical drug testing before human clinical trials
Novartis’ Cosentyx becomes first anti-IL-17 biologic approved for polymyalgia rheumatica
Novartis has received approval from the US Food and Drug Administration FDA for Cosentyx secukinumab mg to treat adults with polymyalgia rheumatica PMR who have not responded adequately to corticosteroids or cannot tolerate a reduction in their corticosteroid dose



